Invention Grant
- Patent Title: FGFR1 extracellular domain combination therapies for lung cancer
- Patent Title (中): FGFR1细胞外结构域联合治疗肺癌
-
Application No.: US13296168Application Date: 2011-11-14
-
Publication No.: US08951972B2Publication Date: 2015-02-10
- Inventor: Li Long , Thomas Brennan
- Applicant: Li Long , Thomas Brennan
- Applicant Address: US CA South San Francisco
- Assignee: Five Prime Therapeutics, Inc.
- Current Assignee: Five Prime Therapeutics, Inc.
- Current Assignee Address: US CA South San Francisco
- Agency: Casimir Jones, S.C.
- Main IPC: A61K38/00
- IPC: A61K38/00 ; A61K39/00 ; A61P35/00 ; C07K16/00 ; C12P21/00 ; A61K38/17 ; A61K39/395 ; A61K45/06 ; A61K38/38 ; A61K31/337 ; A61K31/4745 ; A61K31/475 ; A61K31/513 ; A61K31/519 ; A61K31/555 ; A61K31/704 ; A61K31/7048 ; A61K33/24
Abstract:
Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.
Public/Granted literature
- US20120237511A1 FGFR1 EXTRACELLULAR DOMAIN COMBINATION THERAPIES Public/Granted day:2012-09-20
Information query
IPC分类:
